IGF1 and hyperinsulinism: Hyperinsulinism in patients with exogenous obesity leads to an increment in GV by increasing insulin-like growth factor 1 (IGF-1) production and bioavailability or showing a cross-reaction with IGF-1 receptors (1,13).